GSK Lifts Long-Term Outlook on Drug Pipeline, Buys Back Shares
GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around ...
GSK Launches $2.5 Billion Buyback, Raises Midterm Sales Outlook
The pharmaceutical company said promising pipeline developments and high demand for drugs in its specialty segment lifted ...
FTSE 100 climbs after temporary easing of Trump tariff fears
The biggest fallers on the FTSE 100 were Diageo, down 92.5p to 2235p, DCC, down 195p to 5300p, Croda, down 103p to 3110p, ...
GSK launches £2bn buyback plan, lifts long-term guidance
GSK today increased its 2031 sales outlook to more than £40 billion, up from £38 billion amid stronger progress in its late-stage drugs pipeline. This improves to 7% at constant exchange rates. Core ...
Evening Standard on MSN9d
GSK and Oxford researchers to create cancer vaccine to stop disease developing
GSK will invest up to £50 million in the new project, which could inform future development of cancer vaccines.
Buy10h
LONDON BRIEFING: GSK hails pipeline as ups 2031 sales target
In early UK corporate news, GSK announced a buyback and upped its 2031 sales target. Here is what you need to know at the London market open: FTSE 100: called down 0.3% at 8,542.57 Hang Seng: down 1.0 ...
The Financial Times28d
GSK nears $1bn deal for biotech developing drug for rare tumour
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. GSK is nearing a $1bn deal to buy a US biotech developing a treatment for rare gastrointestinal tumours ...